Connor, Clark & Lunn Investment Management (CC&L)
CMPX icon

Connor, Clark & Lunn Investment Management (CC&L)’s Compass Therapeutics CMPX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.63M Buy
497,818
+306,094
+160% +$1.77M 0.01% 873
2025
Q4 		$1.03M Buy
+191,724
New +$885K ﹤0.01% 1119
2025
Q1 		– Sell
-156,871
Closed -$227K – 1438
2024
Q4 		$227K Sell
156,871
-75,178
-32% -$125K ﹤0.01% 1301
2024
Q3 		$427K Buy
232,049
+524
+0.2% +$653 ﹤0.01% 1138
2024
Q2 		$232K Sell
231,525
-9,275
-4% -$13.5K ﹤0.01% 1235
2024
Q1 		$477K Buy
240,800
+27,835
+13% +$48.1K ﹤0.01% 1123
2023
Q4 		$332K Buy
212,965
+80,173
+60% +$139K ﹤0.01% 1149
2023
Q3 		$262K Buy
132,792
+17,746
+15% +$43.9K ﹤0.01% 1178
2023
Q2 		$366K Buy
115,046
+92,495
+410% +$290K ﹤0.01% 1062
2023
Q1 		$73.7K Buy
+22,551
New +$88.5K ﹤0.01% 1178

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Connor, Clark & Lunn Investment Management (CC&L)'s CMPX Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Compass Therapeutics (CMPX) stake by 160% in Q1 2026, buying an estimated $1.77M and bringing the position to 497,818 shares worth $2.63M. The position accounts for 0.01% of the portfolio, ranked #873.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CMPX in Q1 2023 and has held it in 10 quarters since. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 497,818 shares of Compass Therapeutics worth $2.63M as of Q1 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) bought 306,094 Compass Therapeutics shares in Q1 2026, an estimated $1.77M.
  • Compass Therapeutics made up 0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #873 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Compass Therapeutics in Q1 2023 and has held it in 10 quarters since.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.